the staff of the Ridgewood blog
Ridgewood NJ, Aducanumab is the first new treatment for Alzheimer’s disease that has been approved for use in the US in nearly 20 years. It targets the underlying cause of the disease rather than its symptoms. While it is not a miracle drug, its approval will be a huge boost to dementia research. Alzheimer’s disease affects more than 30 million people around the world, most over the age of 65.
